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Utility and limitations of Hepascore 
and transient elastography 
to detect advanced hepatic fibrosis 
in HFE hemochromatosis
Sim Yee Ong1,2,3, Tiffany Khoo4, Amanda J. Nicoll3,5, Lyle Gurrin6, Thomas Worland5, 
Puraskar Pateria4, Louise E. Ramm7, Adam Testro8, Gregory J. Anderson9, 
Richard Skoien10,11, Lawrie W. Powell9,10, Grant A. Ramm7, John K. Olynyk4,12,14* & 
Martin B. Delatycki1,2,13,14
Aspartate aminotransferase-to-platelet ratio index (APRI) and Fibrosis-4 Index (Fib4) have been 
validated against liver biopsy for detecting advanced hepatic fibrosis in HFE hemochromatosis. 
We determined the diagnostic utility for advanced hepatic fibrosis of Hepascore and transient 
elastography compared with APRI and Fib4 in 134 newly diagnosed HFE hemochromatosis subjects 
with serum ferritin levels > 300 µg/L using area under the receiver operator characteristic curve 
(AUROC) analysis and APRI- (> 0.44) or Fib4- (> 1.1) cut-offs for AHF, or a combination of both. 
Compared with APRI, Hepascore demonstrated an AUROC for advanced fibrosis of 0.69 (95% CI 0.56–
0.83; sensitivity = 69%, specificity = 65%; P = 0.01) at a cut-off of 0.22. Using a combination of APRI and 
Fib4, the AUROC for Hepascore for advanced fibrosis was 0.70 (95% CI 0.54–0.86, P = 0.02). Hepascore 
was not diagnostic for detection of advanced fibrosis using the Fib4 cut-off. Elastography was not 
diagnostic using either APRI or Fib4 cut-offs. Hepascore and elastography detected significantly 
fewer true positive or true negative cases of advanced fibrosis compared with APRI and Fib4, except 
in subjects with serum ferritin levels > 1000 µg/L. In comparison with APRI or Fib4, Hepascore or 
elastography may underdiagnose advanced fibrosis in HFE Hemochromatosis, except in individuals 
with serum ferritin levels > 1000 µg/L.
HFE hemochromatosis (HH) is an inherited iron overload disorder, most commonly due to homozygosity for 
the p.C282Y substitution in the HFE protein. The prevalence of homozygosity for this mutation approximates 1 
in 190 in populations of northern European descent. It is now detected in the majority of individuals at early pre-
clinical stages with readily available genetic and biochemical  tests1–6. Early diagnosis and treatment normalises 
life expectancy and can prevent development of  complications7–9. One of the main determinants of morbidity in 
HH is advanced hepatic fibrosis or cirrhosis (herein after termed advanced hepatic fibrosis, AHF)7,8. The term 
AHF encompasses Scheuer grades F3 and F4  fibrosis10. The ‘gold standard’ for assessing AHF has been through 
the use of liver biopsy. Currently, liver biopsy is recommended only in HH individuals with serum ferritin 
levels > 1000 µg/L and age greater than 40 years with abnormal liver function tests and/or  hepatomegaly7,11, as 
it is not without  complication12,13. For this reason, noninvasive approaches for diagnosis of AHF have gained 
 traction14–16.
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Some noninvasive fibrosis biomarkers have been validated against liver biopsy for detection of AHF in HH. 
The aspartate aminotransferase (AST)-to-platelet ratio index (APRI, cut-off value > 0.44) and Fibrosis-4 Index 
(Fib4, cut-off value > 1.1) demonstrate good diagnostic utility for the detection of AHF in HH with area under 
the receiver operator characteristic curve (AUROC) of 0.88 and 0.86, correctly identifying liver biopsy-diagnosed 
AHF in 85% and 80% of cases,  respectively17. Another commonly used biomarker, Hepascore, is also available 
for detection of AHF in chronic liver diseases, but has not been validated in HH. Hepascore incorporates some 
of the markers of fibrogenesis and fibrinolysis to predict  AHF18. It assesses clinical variables of sex and age and 
combines these with blood-based markers including bilirubin, gamma-glutamyl transferase (GGT), hyaluronic 
acid and alpha2-macroglobulin. A cut-off value for Hepascore > 0.50 has been suggested to be predictive of AHF 
in a range of different liver diseases other than  HH18,19.
Transient elastography (TE) is an increasingly common non-invasive method fer detecting AHF in a range 
of liver diseases, but has not been validated in  HH20–27. It relies on mechanical or acoustic modalities generating 
shear waves which are measured by ultrasound and converted to a stiffness estimate. It can be rapidly performed 
in an outpatient setting and provides immediate results. Limited studies have evaluated the performance of TE in 
subjects with  HH28,29. Although liver biopsy was not performed in these studies, all subjects with TE > 8.7 kPa had 
evidence of AHF as determined noninvasively via the Fibrotest, Hepascore, Forns and Fib4  indices28. Since APRI 
and Fib4 have been recently validated as noninvasive biomarkers of advanced hepatic fibrosis in  HH17, the aims of 
our study were to (1) determine the diagnostic utility of Hepascore and TE in comparison with APRI- and Fib4-
determined cut-offs for the detection of probable AHF, and (2) evaluate their responses to phlebotomy treatment.
Patients and methods
Study participants. Newly diagnosed HH subjects were prospectively recruited between August 2012 to 
January 2018 across four different sites in Australia (Austin Health and Eastern Health in Victoria, the Royal Bris-
bane and Women’s Hospital, QIMR Berghofer Institute in Queensland, and Fiona Stanley Hospital in Western 
Australia) via referrals from medical practitioners, pathology companies which perform HFE genetic testing and 
through the Australian Red Cross LifeBlood Service. Inclusion criteria were homozygosity for HFE p.Cys282Tyr, 
age greater than 18 years and a serum ferritin level of more than 300 µg/L. Individuals were excluded if they had 
a history of significant alcohol intake (defined as > 60 g/day for males and > 40 g/day for females), a body mass 
index (BMI) of more than 35 kg/m2, were pregnant or had known liver disease from a cause other than HH. 
Patient demographics and clinical information were recorded. Liver biopsy was not a requirement for entry into 
the  study7,8.
Blood was collected for measurement of serum ferritin level, transferrin saturation and parameters required 
for calculating the noninvasive biomarkers of fibrosis including platelets, ALT, AST, GGT, bilirubin, alpha-
2-macroglobulin and hyaluronic acid. Noninvasive biomarker panel scores were calculated according to the 
following formulae:
• APRI: [(AST (U/L)/upper limit of normal) × 100/ platelet count  (109/L)]16
• Fib4: [age (years)  × AST (U/L)] / [platelet count  (109/L)  × ALT (U/L)½]15
• Hepascore: y/(1 + y), where y = exp [(-4.185818 – 0.0249 × age + 0.7464 × sex (male = 1, 
female = 0) + 1.0039 × α-2-macroglobulin (g/L) + 0.0302 × hyaluronic acid (µg/L) + 0.0691 × bilirubin (µmol/L) 
– 0.0012 × GGT (U/L)]18.
All subjects underwent TE by experienced and accredited operators using the Echosens FibroScan device as 
per the manufacturer’s recommendations. Transducer placement was at 9/10 or 10/11 rib spaces. A reliable data 
set was defined as an interquartile range/median value ratio × 100 equalling less than 30%.
We evaluated two noninvasive biomarker models for the detection of AHF in HH (models 1 and 2):
Model 1 used individual values for APRI > 0.44 or Fib4 > 1.1 to define the presence of probable noninvasive 
biomarker-detected AHF (nAHF). Absence of nAHF was defined by APRI ≤ 0.44 or Fib4 ≤ 1.1 (termed ‘no 
nAHF’). The Hepascore and TE measurements were compared against APRI or Fib4 in the nAHF and ‘no 
nAHF’ groups.
Model 2 was based on the combination of APRI > 0.44 and Fib4 > 1.1 to define the presence of nAHF, similar 
to the method used by Papadopoulos et al.30. Based on the data of Chin et al.17 67% of all HH subjects who had 
both APRI > 0.44 and Fib4 > 1.1 had AHF confirmed by liver biopsy. Of those who had both APRI ≤ 0.44 and 
Fib4 ≤ 1.1, 97% did not have AHF. For model 2, nAHF was defined as being present when subjects had both 
an APRI > 0.44 and a Fib4 > 1.1. Absence of nAHF was defined as both APRI ≤ 0.44 and Fib4 ≤ 1.1 in the same 
subject (no nAHF). Subjects with an elevation in only one of either APRI or Fib4 values (i.e. above the respective 
nAHF cut-offs) were classified as ‘indeterminate’. The Hepascore and TE values were compared in the nAHF 
and ‘no nAHF’ groups.
All subjects provided informed consent. Human Research Ethics approvals were obtained from Austin Health 
(HREC/15/Austin/56 and HREC/12/Austin/19), Eastern Health (LR81/2015), Queensland Metro North Hospi-
tal and Health Service (HREC/15/QRBW/502) and the Western Australian South Metropolitan Health Service 
(15-147).
Statistical analysis. Data are presented as the mean ± SE, unless otherwise specified. Comparisons between 
continuous variables were performed using analysis of variance or t-test (unpaired or paired) whilst categori-
cal analysis was conducted using chi-square analysis. AUROC curve analysis was performed for evaluation of 
diagnostic performance, sensitivity and specificity of Hepascore and TE in comparison with either APRI or Fib4 
(Model 1) or the combination of APRI and Fib4 (Model 2) (Prism 9.0, GraphPad Software). Cut-off values for 
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Hepascore or TE were derived for the maximal combination of sensitivity and specificity(Youden’s index) in each 
AUROC analysis. Statistical significance was defined as P < 0.05.
Data transparency statement. No data, analytical methods or study materials will be made available to 
other researchers.
Statement on guidelines. This study is in compliance with the Australian Code for the Responsible Con-
duct of Research, 2018.
Results
A total of 150 individuals were recruited to the study. There were incomplete data for 16 individuals, leaving a 
cohort of 134 people. The population was predominantly male (68%) with a mean age of 44 years. The mean 
BMI was 26.5 kg/m2. Liver biochemistry was within accepted reference ranges, as were the platelet count and 
international normalised ratio (INR) (Table 1). The mean serum ferritin level of the cohort was 691 µg/L with 
20 subjects having a serum ferritin level > 1000 µg/L.
Model 1—performance of Hepascore and TE in comparison with either APRI or Fib4. Eighteen 
of 134 subjects (13%) had an APRI > 0.44 (nAHF) whilst 116 had an APRI ≤ 0.44 (87%, no nAHF) (Fig. 1A). 
The AUROC curve analysis for the diagnosis of nAHF based on elevated APRI demonstrated that Hepascore 
had an AUROC of 0.69 (95% CI 0.56–0.83, P = 0.01) and a maximum sensitivity and specificity of 69% and 65%, 
respectively, at a cut-off value of 0.22 (Fig. 2A). TE had an AUROC of 0.55 (95% CI 0.38–0.71, P = 0.56), and 
a maximum sensitivity and specificity of 56% and 56%, respectively, at a cut-off value of 4.85 kPa (Fig. 2B). Of 
the 18 subjects with APRI values consistent with nAHF, 11 were detected with Hepascore > 0.22 (61% true posi-
tive, 39% false negative, P < 0.01, Chi-square) and 9 with TE > 4.85 kPa (50% true positive, 50% false negative, 
P < 0.001, Chi-square). Of the 116 subjects with APRI values ≤ 0.44, 84 were detected with Hepascore ≤ 0.22 (72% 
true negative, 28% false positive, P < 0.001, Chi-square) and 68 with TE ≤ 4.85 kPa (59% true negative, 41% false 
positive, P < 0.001, Chi-square). Subjects with nAHF classified using APRI had significantly higher serum fer-
ritin, ALT, AST and Hepascore levels compared with those who did not have nAHF (Table 2). Six of 18 subjects 
with APRI-determined nAHF had serum ferritin values > 1000 µg/L; all were detected using Hepascore > 0.22 
or TE > 4.85 kPa.
Forty of 134 subjects (30%) had a Fib4 > 1.1 (nAHF) whilst 94 had a Fib4 ≤ 1.1 (70%, no nAHF) (Fig. 1B). The 
AUROC curve analysis for the diagnosis of nAHF based on elevated Fib4-alone demonstrated that Hepascore 
had an AUROC of 0.54 (95% CI 0.41–0.65, P = 0.52), and a maximum sensitivity and specificity of 49% and 53%, 
respectively, at a cut-off value of 0.19 (Fig. 2C). TE had an AUROC of 0.51 (95% CI 0.40–0.63, P = 0.80), and a 
maximum sensitivity and specificity of 48% and 54%, respectively, at a cut-off value of 4.75 kPa (Fig. 2D). Of 
the 40 subjects with Fib4 values consistent with nAHF, 16 were detected with Hepascore > 0.19 (40% true posi-
tive, 60% false negative, P < 0.001, Chi-square) and 18 with TE > 4.75 kPa (45% true positive, 55% false negative, 
P < 0.001, Chi-square). Of the 94 subjects with Fib4 values ≤ 1.1, 53 were detected with Hepascore ≤ 0.19 (56% 
true negative, 44% false positive, P < 0.001, Chi-square) and 51 with TE ≤ 4.75 kPa (54% true negative, 46% false 
Table 1.  Baseline demographic and biochemical characteristics of study patients. All data are presented as 
the mean ± SE. ALT: alanine aminotransferase; APRI: aspartate aminotransferase to platelet ratio index; AST: 
aspartate aminotransferase; BMI: body mass index; Fib4: fibrosis-4; GGT: gamma-glutamyl transferase; INR: 
international normalised ratio; TE: transient elastography.
Gender (n, male, female) 91, 43
Age (years) 44.4 ± 1.3
BMI (kg/m2) 26.5 ± 0.4
Biochemistry
Serum ferritin (µg/L) 691 ± 43
Serum ferritin > 1000 µg/L (n) 20
Transferrin saturation (%) 66 ± 1.6
Platelets (×109/L) 236 ± 4
ALT (U/L) 35 ± 2
AST (U/L) 26 ± 1
GGT (U/L) 27 ± 2
INR 1.0 ± 0
Noninvasive fibrosis biomarkers
TE (kPa) 5.1 ± 0.2
Hepascore 0.23 ± 0.01
APRI 0.33 ± 0.01
Fib4 0.92 ± 0.04
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positive, P < 0.001, Chi-square). Subjects with nAHF classified using Fib4 had significantly higher age, serum 
ferritin, and AST levels compared with those who did not have nAHF (Table 2). Eight of 40 subjects with Fib4-
determined nAHF had serum ferritin values > 1000 µg/L; 6 of these were detected with Hepascore > 0.19 and 5 
with TE > 4.75 kPa.
Overall for Model 1, Hepascore demonstrated limited diagnostic utility using a cut-off value of 0.22 for 
detecting AHF in comparison with APRI. Hepascore was not diagnostically useful for detection of AHF in 
comparison with Fib4. TE was not diagnostic in comparison with either APRI or Fib4. Both Hepascore and TE 
detected significantly lower numbers of true positive or true negative cases compared with APRI or Fib4, except 
in subjects with serum ferritin levels > 1000 µg/L.
Model 2—performance of Hepascore and TE in comparison with combined APRI and 
Fib4. Thirteen of 134 subjects (10%) had both an elevated APRI and Fib4 and were defined by this model as 
having nAHF (Fig. 1C). Eighty-nine subjects (66%) had APRI and Fib4 values below the cut-off levels and were 
defined as not having nAHF (no nAHF), whilst 32 (24%) were indeterminate. The AUROC curve analysis for 
the diagnosis of nAHF demonstrated that Hepascore had an AUROC of 0.70 (95% CI 0.54–0.86, P = 0.02), and a 
maximum sensitivity and specificity of 64% and 67%, respectively, at a cut-off value of 0.22 (Fig. 3A). TE had an 
AUROC of 0.52 (95% CI 0.31–0.72, P = 0.85), and a maximum sensitivity and specificity of 49% and 50%, respec-
tively, at a cut-off value of 4.75 kPa (Fig. 3B). Seven of 13 nAHF subjects (54% true positive, 46% false negative) 
were detected using Hepascore > 0.22 (P < 0.01, Chi-square) whilst 6 of 13 nAHF subjects (46% true positive, 
54% false negative) were detected using TE > 4.75 kPa (Fig. 1C, P < 0.01, Chi-square). Of the 89 subjects who 
did not have nAHF using this model (no nAHF), Hepascore and TE correctly classified 63 (71% true negative, 
29% false positive, P < 0.001, Chi-square) and 55 (62% true negative, 38% false positive, P < 0.001, Chi-square), 
respectively. Subjects with nAHF classified using Model 2 had significantly higher age, serum ferritin, ALT and 
AST levels compared with those who did not (Table 2). Five of 13 subjects with nAHF had serum ferritin val-
ues > 1000 µg/L, 4 of these were identified with Hepascore > 0.22 and TE > 4.75 kPa.
Overall for Model 2, Hepascore demonstrated some diagnostic utility for detecting AHF, but detected sig-
nificantly lower numbers of true positive and true negative cases compared with APRI and Fib4 combined. TE 
was not diagnostic. Both Hepascore and TE correctly identified likely AHF in most subjects with serum ferritin 
levels > 1000 µg/L.
Response of noninvasive fibrosis markers to phlebotomy treatment. For those subjects classified 
as having nAHF on the basis of APRI > 0.44, there were significant reductions in APRI and serum ferritin levels 
with treatment (Table 3). There were no treatment-related effects on Fib4, TE or Hepascore. Serum ferritin levels 
declined significantly with treatment in those subjects classified as not having nAHF on the basis of APRI ≤ 0.44 
in Model 1. However, there were no treatment-related effects on APRI, Fib4, TE or Hepascore.
For those subjects classified as having nAHF on the basis of Fib4 > 1.1, there were significant reductions in 
APRI, Fib4 and serum ferritin levels with treatment (Table 4). There were no treatment-related effects on TE or 
Hepascore. Serum ferritin levels declined significantly with treatment in those subjects classified as not having 
Figure 1.  (A) Study subjects classified as having noninvasive biomarker detected advanced hepatic fibrosis 
(nAHF) on the basis of APRI > 0.44 (Model 1). Subjects with APRI ≤ 0.44 were classified as not having nAHF 
(no nAHF). The numbers of subjects in each of these categories detected by Hepascore (cut-off 0.22) or transient 
elastrography (TE, cut-off 4.85 kPa) are shown in each box. (B) Study subjects classified as having noninvasive 
biomarker detected advanced hepatic fibrosis (nAHF) on the basis of Fib4 > 1.1 (Model 1). Subjects with 
Fib4 ≤ 1.1 were classified as not having nAHF (no nAHF). The numbers of subjects in each of these categories 
detected by Hepascore (cut-off 0.19) or transient elastrography (TE, cut-off 4.75 kPa) are shown in each box. 
(C) Study subjects classified as having noninvasive biomarker detected advanced hepatic fibrosis (nAHF) on 
the basis of APRI > 0.44 and Fib4 > 1.1. Subjects with APRI ≤ 0.44 and Fib4 ≤ 1.1 were classified as not having 
nAHF (no nAHF). Those subjects not meeting any of the preceding criteria were classified as indeterminate. 
The numbers of subjects in each of the nAHF or no nAHF categories detected by Hepascore (cut-off 0.22) or 
transient elastrography (TE, cut-off 4.75 kPa) are shown in each box.
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nAHF on the basis of Fib4 ≤ 1.1 in Model 1. However, there were no treatment-related effects on APRI, Fib4, 
TE or Hepascore.
In Model 2, there were treatment-related significant reductions in serum ferritin levels in those with or with-
out nAHF (Table 5). However, there were no treatment-related effects in the two fibrosis groups with regards to 
APRI, Fib4, Hepascore or TE.
Discussion
Early diagnosis of AHF in HH is important for guiding clinical management. Since most subjects with HH 
are now detected prior to the development of clinical sequelae of iron overload, there is a need to define useful 
noninvasive methods for assessment of AHF to ensure that only those at highest risk of AHF progress to liver 
biopsy. This type of approach is occurring across a broad spectrum of liver diseases previously dependent on liver 
biopsy for accurate fibrosis  staging24. What is clearly apparent is the variation in cut-off thresholds and suitability 
of these methods in various different liver  diseases24. Furthermore, liver biopsy is not well suited for routine 
follow-up of fibrosis following treatment due to its invasive nature and associated  risks8,9. In HH, APRI and Fib4 
were recently shown to be accurate for detection of liver biopsy-diagnosed AHF with cut-off levels greater than 
0.44 and 1.1,  respectively17. APRI was also useful in monitoring fibrosis regression following treatment. These 
cut-off values in HH were substantially lower than those reported for other liver disease  aetiologies14,15,24. With 
Figure 2.  Receiver-operator characteristic curve analysis for Model 1 comparing Hepascore against APRI > 0.44 
(A), TE against APRI > 0.44 (B), Hepascore against Fib4 > 1.1 (C), or TE against Fib4 > 1.1 (D).
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this knowledge, we designed the current real-world study of community-dwelling subjects with HH to determine 
the utility of two other commonly available noninvasive methods of detecting hepatic fibrosis, Hepascore and 
TE, using APRI- and Fib4-determined cut-offs as surrogates for AHF.
We compared Hepascore and TE with either APRI or Fib4 (model 1) or a combination of APRI and Fib4 
(model 2). Hepascore demonstrated only fair diagnostic utility for the diagnosis of nAHF based on elevated 
APRI (AUROC 0.69, 95% CI 0.56–0.83, P = 0.01) or the combination of APRI and Fib4 (AUROC 0.70, 95% CI 
0.54–0.86, P = 0.02). Nonsignificant diagnostic utility was demonstrated for Hepascore in comparison with Fib4 
(AUROC 0.54, 95% CI 0.41–0.65, P = 0.52). Similarly, TE demonstrated no diagnostic utility for AHF in com-
parison with APRI, Fib4 or the combination of APRI and Fib4. Hepascore (using a cut-off value of 0.22) and TE 
(using a cut-off value of 4.75 kPa) detected significantly less true positive or true negative cases of AHF compared 
with APRI or Fib4, except in subjects with serum ferritin levels > 1000 µg/L. Previously, we showed substantially 
lower cut-off values for APRI and Fib4 for detection of AHF in HH compared to other liver  diseases17. We now 
extend this to demonstrate that Hepascore and TE cut-offs for the detection of AHF in HH are also substantially 
lower compared to other liver  diseases18–27. The lower cut-offs probably reflect the lesser degree of hepatic inflam-
mation which occurs in HFE Hemochromatosis liver injury compared with other liver  diseases8,31.
As all individuals underwent phlebotomy treatment following recruitment into the study, we were able to 
evaluate the responses to treatment of APRI, Fib4, Hepascore and TE. All subjects, irrespective of the presence 
or absence of AHF, demonstrated significant reductions in serum ferritin levels with phlebotomy treatment, as 
expected. Subjects with AHF were older and had higher ALT and/or AST values than those who did not have 
AHF, compatible with previous reports of HH subjects with liver biopsy-confirmed  AHF2,5,8,17,32. Furthermore, 
subjects with nAHF defined on the basis of elevated APRI demonstrated a significant reduction in APRI with 
phlebotomy treatment whilst those defined on the basis of elevated Fib4 demonstrated significant reductions 
in APRI and Fib4 with treatment. There were no statistically significant phlebotomy treatment-related effects 
on Hepascore and TE in subjects with or without nAHF. Our observations are consistent with previous studies 
Table 2.  Characteristics of study subjects in Model 1 (APRI or Fib4) and Model 2 (combined APRI and 
Fib4 scores). All data are presented as the mean ± SE. ALT: alanine aminotransferase; APRI: aspartate 
aminotransferase to platelet ratio index; AST: aspartate aminotransferase; Fib4: fibrosis-4; GGT: gamma-
glutamyl transferase; nAHF: noninvasive biomarker advanced hepatic fibrosis; No nAHF: no noninvasive 
biomarker advanced hepatic fibrosis; TE: transient elastography. *P < 0.05, **P < 0.01, ***P < 0.0001 compared 




 Gender (n, male, female) 12, 6 78, 38
 Age (years) 48 ± 4 44 ± 1
 Ferritin (µg/L) 1118 ± 191 625 ± 37***
 Transferrin saturation (%) 74 ± 4 65 ± 2
 ALT (U/L) 73 ± 11 29 ± 1***
 AST (U/L) 46 ± 5 23 ± 0.7***
 Hepascore 0.35 ± 0.06 0.21 ± 0.01**
 TE (kPa) 5.9 ± 0.9 4.9 ± 0.13
Fib4
 Gender (n, male, female) 27, 13 64, 30
 Age (years) 57 ± 1.6 39 ± 1***
 Ferritin (µg/L) 875 ± 114 613 ± 35*
 Transferrin saturation (%) 67 ± 3 65 ± 2
 ALT (U/L) 37 ± 3 34 ± 3
 AST (U/L) 31 ± 1 25 ± 1*
 Hepascore 0.27 ± 0.04 0.22 ± 0.01
 TE (kPa) 5.4 ± 0.4 4.9 ± 0.1
Model 2
Gender (n, male, female) 8, 5 60, 29
Age (years) 56 ± 3 40 ± 1***
Ferritin (µg/L) 1188 ± 250 595 ± 34***
Transferrin saturation (%) 74 ± 4 65 ± 2
ALT (U/L) 54 ± 6 29 ± 1***
AST (U/L) 38 ± 3 22 ± 1***
Hepascore 0.17 ± 0.11 0.05 ± 0.02
TE (kPa) 6.0 ± 1.1 4.9 ± 0.1
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which have shown significant reductions in APRI following phlebotomy treatment of subjects with liver biopsy 
confirmed  AHF17.
The majority of individuals with HH in our study did not have evidence of AHF and most had serum ferritin 
levels < 1000 µg/L. Using APRI, Fib4 or the combination of APRI and Fib4, we observed a likelihood of AHF in 
Figure 3.  Receiver-operator characteristic curve analysis for Model 2 comparing either Hepascore (A) or TE 
(B) against the combination of APRI > 0.44 and Fib4 > 1.1.
Table 3.  Comparison of noninvasive biomarkers pre- and post-treatment in the subjects with either 
noninvasive biomarker-detected advanced hepatic fibrosis (nAHF) using APRI > 0.44 or no evidence of 
noninvasive biomarker-detected advanced hepatic fibrosis (no nAHF) using APRI ≤ 0.44 in Model 1. Results 
are shown as mean ± SE. APRI: aspartate aminotransferase to platelet ratio index; Fib4: fibrosis-4; nAHF: 
noninvasive biomarker advanced hepatic fibrosis; No nAHF: no noninvasive biomarker advanced hepatic 
fibrosis; TE: transient elastography. *P < 0.05, **P < 0.01, ***P < 0.0001 compared with pre-treatment (paired t 
test).
APRI Fib4 TE Hepascore Ferritin (µg/L)
nAHF
Pre-treatment 0.64 ± 0.05 1.4 ± 0.2 5.9 ± 0.9 0.35 ± 0.06 1118 ± 191
Post-treatment 0.44 ± 0.05* 1.3 ± 0.2 4.5 ± 0.5 0.30 ± 0.08 317 ± 37**
No nAHF
Pre-treatment 0.28 ± 0.01 0.84 ± 0.03 4.9 ± 0.1 0.21 ± 0.01 624 ± 37
Post-treatment 0.30 ± 0.03 0.98 ± 0.13 5.0 ± 0.2 0.20 ± 0.02 338 ± 21***
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13%, 30% or 10% of HH subjects, respectively. Previous population-based studies have reported similar preva-
lences of between 10 and 25% for AHF in subjects at the time of diagnosis, and primarily in those with serum 
ferritin levels > 1000 µg/L at the time of  diagnosis2,5,7,9,32. Interestingly, both Hepascore and TE identified all HH 
subjects who had serum ferritin levels > 1000 µg/L and who had elevation of APRI above 0.44. Hepascore and 
TE identified 6 of 8 HH subjects who had serum ferritin levels > 1000 µg/L and who had elevation of Fib4 above 
1.1. Thus, Hepascore and TE may be more reliable in the subgroup of individuals who have serum ferritin levels 
above 1000 µg/L.
Our study has several strengths and weaknesses. While the relatively small sample size could be considered 
a potential limitation, the strengths of the study include the prospective enrolment and collection of data from 
community-dwelling subjects who were able to be followed-up after phlebotomy treatment. Subjects enrolled in 
our study were not required to undergo liver biopsy for routine clinical care and thus we were unable to compare 
our noninvasive biomarkers with liver-biopsy confirmed fibrosis. However, we believe our use of APRI and Fib4 
cut-off values which have been recently validated against liver biopsy-staged fibrosis in  HH17 is a pragmatic 
alternative given the relative rarity in routine clinical practice of liver biopsy for evaluation of HH.
Conclusion
The use of Hepascore or TE for detection of AHF in HH may lead to underdiagnosis, except when individu-
als have serum ferritin levels elevated above 1000 µg/L. Overall, APRI or Fib4 are more clinically useful than 
Hepascore or TE for detection of AHF.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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